A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.

Saved in:
Bibliographic Details
Title: A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin.
Authors: Vize CJ; Department of Ophthalmology, Hull University Teaching Hospitals NHS Trust, Hull, UK., Kim SK; Department of Ophthalmology and Visual Science, University of Texas McGovern Medical School, Houston, Texas, USA., Matthews T; Birmingham Neuro-Ophthalmology Unit, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK., Macsai M; Northshore University Health System, Glenview, Illinois, USA., Merrell R; NorthShore University Health System, Evanston, Illinois, USA., Hsu S; The Vivian L. Smith Department of Neurosurgery, University of Texas McGovern Medical School, Houston, Texas, USA., Kundu MG; AbbVie, North Chicago, Illinois, USA., Yoon J; AbbVie, North Chicago, Illinois, USA., Kennedy E; AbbVie, North Chicago, Illinois, USA., Pai M; AbbVie, North Chicago, Illinois, USA., Bain E; AbbVie, North Chicago, Illinois, USA., Lassman AB; Division of Neuro-Oncology, Department of Neurology and the Herbert Irving Comprehensive Cancer Center, Columbia University Vagelos College of Physicians and Surgeons and New York-Presbyterian, New York, New York, USA., Moazami G; Department of Ophthalmology, Columbia University Irving Medical Center, New York, NY, USA.
Source: Ophthalmic research [Ophthalmic Res] 2023; Vol. 66 (1), pp. 1030-1043. Date of Electronic Publication: 2023 May 31.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
Journal Info: Publisher: Karger Country of Publication: Switzerland NLM ID: 0267442 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0259 (Electronic) Linking ISSN: 00303747 NLM ISO Abbreviation: Ophthalmic Res Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1423-0259
DOI:10.1159/000531142